OTLC — Oncotelic Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Oncotelic Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -10.5 | 4.68 | -8.21 | -4.78 | 249 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 5.69 | -6.94 | 6.97 | 3.69 | -362 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.333 | 0.8 | -0.086 | 0.348 | 0.106 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -4.43 | -1.45 | -1.32 | -0.74 | -1.38 |
| Financing Cash Flow Items | 1.55 | 0 | -0.125 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.53 | 1.13 | 1.25 | 0.656 | 1.39 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.095 | -0.327 | -0.071 | -0.084 | 0.003 |